Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.

[1]  Cher Heng Tan,et al.  Imaging of gastroenteropancreatic neuroendocrine tumors. , 2011, World journal of clinical oncology.

[2]  R. Valkema,et al.  Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  I. Virgolini,et al.  Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients. , 2010, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[4]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[5]  Haesun Choi,et al.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Visser,et al.  Long-term toxicity of [177Lu-DOTA0,Tyr3]octreotate in rats , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  L. Kvols,et al.  Well-Differentiated Pancreatic Nonfunctioning Tumors/Carcinoma , 2007, Neuroendocrinology.

[8]  L. Kvols,et al.  Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  M. Cremonesi,et al.  Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  S. Weiner,et al.  End-stage renal disease after treatment with 90Y-DOTATOC , 2001, European Journal of Nuclear Medicine.

[11]  M. Mihatsch,et al.  A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[13]  R. Herrmann,et al.  Yttrium-90 DOTATOC: first clinical results , 1999, European Journal of Nuclear Medicine.

[14]  T. Visser,et al.  Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  A. Peters,et al.  Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. , 1993, British Journal of Cancer.

[16]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[17]  R. Jensen,et al.  Gastroenteropancreatic neuroendocrine tumours. , 2008, The Lancet. Oncology.

[18]  R. Valkema,et al.  Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  Raffaella Barone,et al.  Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  Giovanni Paganelli,et al.  Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  Marion de Jong,et al.  Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  R. Valkema,et al.  Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine , 2002, European Journal of Nuclear Medicine and Molecular Imaging.